Tamoxifen for prevention of breast cancer

Annals of Pharmacotherapy

Volumn 37, Issue 2, 2003, Pages 268-273

  Cersosimo, Robert J ^a   Hernández, Lesbia ^b   Gagnon, Louise ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Breast cancer; Cancer prevention; Tamoxifen

Indexed keywords

PLACEBO; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; HEALTH PROGRAM; HOT FLUSH; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

EID: 0037314794     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002800303700219     Document Type: Article

References (30)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002 CA Cancer J Clin 2002;52:23-47.
2. Package insert. Nolvadex (tamoxifen citrate). Wilmington. DE: AstraZenica Pharmaceuticals, May 2002.
3. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Nad Cancer Inst 1998;90:1371-88.
5. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Lancet 1998;352:93-7.
6. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
7. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-4.
8. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
9. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998;352:80-1.
10. Costantino JP, Vogel VG. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. Clin Breast Cancer 2001;2:41-6.
11. Fisher B. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. J Clin Oncol 1999;17:1632-9.
12. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
13. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
14. Fornander T, Hellstrom A-C, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85:1850-5.
15. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88:832-4.
16. Cuenca RE, Giachino J, Arredondo MA, Hempling R, Edge SE. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer 1996;77:2058-63.
17. Assikis VJ, Jordan VC. Tamoxifen and endometrial cancer: from experiment to patient. Recent Res Cancer Res 1996:140:61-71.
18. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
19. Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier J-F, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76:325-30.
20. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7.
21. Gelmon K. One step forward or one step back with tamoxifen? Lancet 2000;356:868-9.
22. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
23. Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? J Clin Oncol 1998;16:779-92.
24. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
25. Taylor AL, Adams-Campbell LL, Wright JT Jr. Risk/benefit assessment of tamoxifen to prevent breast cancer - still a work in progress? J Natl Cancer Inst 1999;91:1792-3.
26. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endomentrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998;47:41-6.
27. ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynaecol Obstet 2001;73:77-9.
28. Hershman D, Sundararajan V, Jacobsen JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high risk women: a cost-effectiveness analysis. J Clin Oncol 2001;20:9-16.
29. Goel V. Tamoxifen and breast cancer prevention: what should you tell your patients? Can Med Assoc J 1998;158:1615-7.
30. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17:1939-55.